Among patients with intensive care unit-acquired weakness (ICUAW), skeletal muscle strength often decreases significantly. The present study aimed to explore the effects of testosterone propotionate on skeletal muscle using rat model of sepsis. Male SD rats were randomly divided into experimental group, model control group, sham operation group and blank control group. Rats in experimental group were given testosterone propionate two times a week, 10 mg/kg for 3 weeks. Maximal contraction force, fatigue index and cross-sectional area of the extensor digitorum longus (EDL) were measured. Myosin, IGF-1, p-AKT and p-mTOR levels in EDL were detected by Western blot. Histological changes of the testis and prostate were detected by hematoxylin and eosin staining. We found that maximal contraction force and fatigue index of EDL in experimental group were significantly higher than in model control group. Cross-sectional area of fast MHC muscle fiber of EDL in group was significantly higher than in model control group. The levels of myosin, IGF-1, p-AKT and p-mTOR of EDL in experimental group were significantly higher than in model control group. In addition, no testicle atrophy and prostate hyperplasia were detected in experimental group. In conclusion, these results suggest that testosterone propionate can significantly improve skeletal muscle strength, endurance and volume of septic rats, and the mechanism may be related to the activation of IGF-1/AKT pathway. Moreover, testosterone propionate with short duration does not cause testicular atrophy and prostate hyperplasia in septic rats. Therefore, testosterone propionate is a potential treatment for muscle malfunction in ICUAW patients.
Introduction
Intensive care unit-acquired weakness (ICUAW) is common in critically ill patients who have decreased muscle strength and weakened peripheral nerve excitability. [1] At present, it is generally believed that the occurrence of ICUAW is related to multiple factors, including sepsis, multi-organ failure and mechanical ventilation, among which sepsis is the most prominent [2] . ICUAW affects approximately 40% of critically ill patients, and even 50-100% patients with severe sepsis [3] . Therefore, prevention and treatment of ICUAW have become an urgent medical issue [4] .
Testosterone is a major male hormone applied in clinical practice in elderly men and patients with severe burns and other weaknesses to improve muscle function and quality of life [5] . In animal experiments, testosterone improved the muscle function of paraplegia, limb fracture and castration [6, 7] . In the clinical, testosterone was associated with metabolic syndrome [8] . Therefore, determining whether the appropriate testosterone supplements can be given to ICUAW patients need further studies.
ICUAW patients often show skeletal muscle atrophy. One major role of testosterone is to promote the synthesis of skeletal muscle protein by acting on a series of cellular signals through androgen receptors [9, 10] . In addition, testosterone promotes the proliferation of vascular endothelial cells to increase local blood and oxygen supply of muscles, ultimately increasing muscle volume, strength and endurance [11] . Clinical and animal studies have shown that testosterone can significantly increase the expression of tissue and circulating insulin-like growth factor 1 (IGF1), which activates Akt/m-TOR pathway to regulate skeletal muscle [12] .
Therefore, the present study aimed to investigate the effect and possible mechanism of testosterone on muscle weakness in rat model with sepsis.
Materials and methods

Animals
Animal experiments were conducted at Chongqing Medical University in accordance with "Chongqing Administrative Measures on Experimental Animals" and approved by the ethics committee of Chongqing Medical University. Healthy male SD rats were purchased from the Animal Experiment Center of Chongqing Medical University (license number scxk-2017-0001) and raised in an SPF level animal house. Rats were fed standard feed at room temperature (20 • C), with a circadian rhythm of 12 h of day alternated with 12 h of night.
The rats were anesthetized with pentobarbital salt solution (40 mg/kg) via intraperitoneal injection, and then cecal ligation and perforation (CLP) was performed in experimental group and model control group to establish the animal model of sepsis. Briefly, midline laparotomy was performed, and the cecum was exteriorized and ligated distal to the ileo cecal valve without causing intestinal obstruction. Next, the cecum was perforated with a 20-gauge needle and squeezed gently to extrude a small amount of fecal contents from the punctured cecum into the abdominal cavity. The cecum was then returned to the peritoneal cavity and the incision was closed with sutures [13] . The cecum was exteriorized without ligation and puncture in sham operation group. The blank control group did not receive any operation. All rats were administrated intraperitoneally with saline to recover fluid loss immediately after the operation and then allowed free access to chow and water. Total 25 rats were subjected to CLP and 9 rats died within 3-4 days after CLP, the mortality rate was 36%. The other 16 rats survived till the end of experiments, and they were randomly divided into experimental group and model control group (n = 8) using computer-generated numbers. The 8th day after surgery, hind limb was fixed, and a 1-ml sterile empty needle was used for vertical puncture into the muscle. Sterile cotton balls were used for compression and hemostasis after injection, and the hind limbs on both sides were injected with testosterone propionate (Guangzhou Baiyunshan pharmaceutical) twice a week, 10 mg/kg for 3 weeks for rats in experimental group; rats in model control group were injected with same amount of soybean oil with the same injection method and date. Rats in sham group and blank control group (n = 8) were not injected.
Determination of serum testosterone
One milliliter of blood was collected from the rats by the orbital blood collection method. The serum testosterone concentration was determined by radioimmunoassay using 125 I testosterone radioimmunoassay kit for rat (Beijing Furuirunze Biotechnology Co, LTD). 
Maximum contractile force, contraction time, relaxation time and fatigue index
Rats were anesthetized with pentobarbital and were placed on a mat heated to 37 • C. The sciatic nerve was dissected intact through a left hip incision, and small branches of the sciatic nerve innervating the hip muscle were cut off, leaving only the anterior tibial nerve. A longitudinal incision was made in the middle of the foot, and the extensor digitalis longus (EDL) was disassociated along the tendon, while all blood vessels were preserved. The rats were placed in prone position, with the foot fixed at 90 • of the ankle, and the femur fixed with clamps at an angle of approximately 100 • between the femur and the tibia [14] . The tendon of EDL with the tension transducer was connected with an inelastic thread, and the sciatic nerve was gently placed on the hook of a bipolar electrode. A macro-adjuster was used to extend the length of EDL gradually by 1 mm each time until the contraction force decreased. The length of EDL corresponding to the maximum contraction force was the optimal initial length. EDL was relaxed and returned to the state of natural relaxation, the optimal initial length was recorded, and all measurements were determined under this length. The contraction time is defined as the time from the beginning of the contraction to the maximum peak, and the relaxation time is defined as the time from the peak to the baseline. The percentage of the final contraction force to beginning contraction force of EDL was named the fatigue index of the rat toe extensor [15] . 
Muscle, testicle and prostate specimen collection
Rats were killed by high-dose pentobarbital (100 mg/rat) and high carbon dioxide. The standard of death was loss of consciousness, respiratory arrest and electrocardiogram. EDL of the right leg was cut off and frozen at −80 • C, while the middle segment of the left EDL, testicle and prostate tissue were cut off and fixed in 4% paraformaldehyde.
Western blot analysis
EDL was homogenized in ice-cold lysis buffer (pH 7.4) containing 50 mM Tris-base, 1% (v/v) Triton X-100, 0.25% (v/v) sodium desoxycholate, 150 mM NaCl, 1 mM EDTA, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 5 mM DTT and 1 mM PMSF. All homogenates were centrifuged at 12,000 × g, 4 • C for 10 min, and the supernatants were centrifuged at 100,000 × g at 4 • C for 1 h. The protein concentration was determined using the Bradford Protein Assay Kit (Beyotime, China). Soluble proteins (20 μg) were used for Western blotting with primary antibodies against AKT1/2/3 (rabbit monoclonal antibody; EPR16798 Abcam; 1:10,000), mTOR (rabbit monoclonal antibody; Y391 Abcam; 1:2000), mTOR phosphor S2481 (rabbit monoclonal antibody; EPR427(N) Abcam; 1:5000), AKT1/2/3 phospho Y315 + Y316 + Y312 (rabbit polyclonal antibody; Abcam; 1:1000) and fast myosin skeletal heavy chain (rabbit polyclonal antibody; Abcam; 1 μg/ml) and goat anti rabbit IgG (Abcam, 1:5000). Chemiluminescence was performed using a super ECL plus (Beyotime, China), and the blots were exposed to a Gel Imaging System (Bio-Rad, America).
Histological analysis
The frozen EDL tissues were sliced with a Cryostat Microtome (Leica, Germany). Immunohistochemical analysis of the sections was performed using fast myosin skeletal heavy chain antibody (Abcam, ab91506, U.K.), and the staining was analyzed with Image Pro Plus 6 software. The testicle and prostate tissues were sectioned for hematoxylin and eosin (HE) staining, and observed under an optical microscope (Olympus Optical, Japan).
Statistical analysis
All data were expressed as Mean + − standard deviation (SD) and analyzed by SPSS 21.0 software. For data with normal distribution, one-way ANOVA was used to compare the difference, and for data not in normal distribution, Mann-Whitney U test was used to compare the difference. P < 0.05 was considered significant.
Results
Changes in body weight and serum testosterone concentration in each group
Preoperative body weight of rats among each group showed no significant difference. Body weight of rats in experimental group and model control group significantly decreased compared with sham group and blank control group on the 8th day after surgery before testosterone treatment (P < 0.01), and there was no significant difference between experimental group and model control group. After 3 weeks of treatment, the body weight of experimental group and model control group was still significantly lower than sham operation group and blank control group (P < 0.01), and there was no significant difference between experimental group and model control group. Three weeks after intramuscular injection of testosterone propionate, serum testosterone concentration in experimental group was significantly higher than three groups (P < 0.01, Figure 1 ).
Testosterone improved the strength of EDL
The maximal contractile force of EDL was significantly greater in experimental group than in model control group, while it was also significantly greater in sham operation group and blank control group than in model control group (Figure 2A) . Moreover, the contraction time of EDL was significantly shorter in experimental group than in model control group (Figure 2B ). In addition, the fatigue index of EDL was significantly higher in experimental group than in model control group, while it was also significantly higher in sham operation group and blank control group than in model control group (Figure 2C) . Collectively, these data indicate that testosterone improved the strength of EDL.
Testosterone improved the muscle of EDL
The cross-sectional area of MHC fast muscle fibers of EDL was significantly larger in experimental group than in model control group, while it was also significantly larger in sham operation group and blank control group than in model control group ( Figure 3A) . Moreover, the microvessel density of EDL was significantly higher in experimental group than in model control group (Figure 3B ). Collectively, these data indicate that testosterone improved the muscle and angiogenesis of EDL.
Testosterone enhanced the expression of IGF-1 and activated Akt/mTOR signaling in EDL
To reveal the mechanism by which testosterone improved the muscle function of EDL, we detected the expression of IGF-1 in EDL. Western blot analysis showed that IGF-1 protein level in EDL was significantly higher in experimental group than in model control group, sham operation group and blank control group ( Figure 4A) . Moreover, levels of phosphorylated (activated) AKT and mTOR in EDL were significantly higher in experimental group than in control group, sham operation group and blank control group ( Figure 4B ). In addition, protein level of fast myosin skeletal heavy chain (MHC) was significantly higher in experimental group than in model control group, and it was also significantly higher in sham operation group and blank control group than in model control group (Figure 4C ).
Testosterone did not cause pathological changes in the testis and prostate
HE staining of the testes in experimental group showed no significant atrophy compared with model control group, sham operation group and blank control group ( Figure 5 ). HE staining of the prostate in experimental group showed no significant hyperplasia compared with model control group, sham operation group and blank control group (Figure 6 ).
Discussion
Sepsis is one of the important causes of acquired muscle weakness in either human or rats, with a high incidence and severe symptoms of ICUAW. The sepsis rat model is one of the most commonly used ICUAW animal models, and the cecal ligation perforation method can not only simulate clinical manifestations of sepsis caused by intestinal perforation and intestinal necrosis, but also adjust the severity of sepsis by controlling the length of the cecal ligation [16] . Therefore, we chose rat sepsis model as a suitable animal model to develop new treatment for ICUAW.
Sepsis, especially severe sepsis, can lead to a significant decrease in serum testosterone levels in either patients or experimental animals, which is currently thought to be caused by the suppression of the hypothalamic-pituitary-gonadal axis by systemic inflammatory response syndrome [17] . In view of the powerful role of testosterone in enhancing exercise endurance, we wondered whether testosterone can improve the symptoms of muscle atrophy following sepsis.
Testosterone propionate is an artificial testosterone preparation that has a long half-life after intramuscular injection. Testosterone propionate has been used to treat severe burns and elderly patients with frailty. The typical clinical manifestations of ICUAW include muscle weakness, muscular atrophy and decreased exercise endurance. In the present study, we found that testosterone propionate promoted maximum contraction force, fatigue index, average cross-sectional area of muscle fiber of rats with sepsis-acquired muscle weakness after short term application. These data indicate that testosterone could enhance the skeletal muscle of rats with sepsis-acquired muscle weakness in strength, endurance and volume. Moreover, the contraction time of EDL in experimental group was significantly shorter than that in model control group, indicating that skeletal muscle was more excitatory and responsive after testosterone treatment. In addition, rapid myosin degradation is one characteristic of ICUAW, and testosterone significantly increased the expression of rapid myosin in the skeletal muscle of rats with sepsis, which indicate that testosterone could improve the muscle in condition of ICUAW.
IGF-1/AKT pathway is one of the main signaling pathways that regulate skeletal muscle anabolism and skeletal muscle function [18] . IGF1 is an important growth factor and potent activator of AKT to increase muscle protein synthesis and decrease protein degradation by activating downstream AKT/mTOR pathway, which may lead to increased muscle strength [19] . In the present study, serum testosterone level, IGF-1 protein level, phosphorylated AKT and mTOR levels and rapid myosin expression level all significantly increased in EDL of experimental group. Furthermore, testosterone propionate has androgen-like effects. Long-term usage of exogenous androgen may inhibit male gonads, and common complications include testicular atrophy and prostatic hyperplasia, which severely limits its clinical application [20] . Therefore, medicinal plants have been exploited to screen new agents with androgen-like effects [21, 22] . Based on histological characteristics of the prostate and testis of rats in experimental group and other groups, we found no significant pathological changes of the prostate and testis in experiment group, which indicates that testosterone propionate may be safe for short-term use.
In summary, our study provides evidence that testosterone propionate can significantly improve skeletal muscle strength, endurance and volume of septic rats, and the mechanism may be related to the activation of IGF-1/AKT pathway, which could be further validated with AKT inhibitors. Moreover, testosterone propionate with short duration does not cause testicular atrophy and prostate hyperplasia in septic rats. However, further clinical trials are needed to validate that testosterone propionate is a potential treatment for muscle malfunction in ICUAW patients.
